cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 12 Documents
 1   2 
Search results for , issue "Vol 16, No 4 (2022): December" : 12 Documents clear
Metaplastic Breast Carcinoma (MBC), Primary Squamous Cell Carcinoma Subtype in A 49-Year-Old Woman: A Case Report Putu Erika Paskarani; Ni Gusti Ayu Agung Manik Yuniawaty Wetan; Ni Putu Sriwidyani; Sang Ayu Putu Yuliantini
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.932

Abstract

Introduction: Metaplastic Breast Carcinoma (MBC) is quite a challenging case because metaplastic breast cancer is one of the rarest subtypes of invasive breast cancer. It is reported that MBC occurs only 0.2 to 1% throughout the world. The metaplastic changes can be squamous cells or other mesenchymal cell types. Clinically, MBC presents as a large palpable mass and may be associated with rapid growth. The size of MBC tends to be larger compared with other types of invasive breast cancer ranging from 1 to more than 10 cm. Although there are several main categories of MBC, some carcinoma can be difficult to classify due to their unusual histologic patterns. This case report study is to provide a clinicopathological overview and approach to MBC.Case Presentation: We reported a 49-year-old woman who suffered from a breast mass that rapidly grew for less than one year. The microscopic findings showed squamous cell carcinoma. While molecular studies revealed triple negative results for hormone receptors although Human Epidermal Growth Factor Receptor 2 (HER2) overexpression was unusual (< 5%). Then, we confirmed with chromogen in situ hybridization (CISH) and there was no gen amplification for HER2. Microscopically, we found ductal carcinoma in situ and this finding supported breast origin.Conclusions: Metaplastic carcinoma did not have any specific and distinctive signs clinically. Metaplastic carcinoma can be monophasic (with only a metaplastic component) or biphasic with two or more components. As treatment options, our patient received conventional chemotherapy. Metaplastic breast cancer is reported to have a lower response rate to conventional adjuvant chemotherapy and worse clinical outcome after chemotherapy than other forms of triple-negative breast cancer.
Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors Raehan Satya Deanasa; Mulawan Umar; Agita Diora Fitri
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.905

Abstract

Background: There is still a limited number of studies related to overall survival in breast cancer patients in Indonesia. This study determines the overall survival and the factor which can affect the survival of stage III breast cancer patients.Methods: This study was a retrospective study. Patients first diagnosed with stage III breast cancer from January 1 to August 31, 2018, at DR. Mohammad Hoesin General Hospital Palembang had been studied. The primary outcome of this study was overall survival. The sociodemographic, clinicopathology, and treatment factors were analyzed to identify the independent variables associated with overall survival using Kaplan-Meier and Cox proportional hazard regression.Results: In this study, 78 samples were included. The 3-year overall survival for stage III breast cancer was 71%. In the bivariate analysis, several factors including older age (> 40) (HR = 2.795, 95% CI 1.223–6.387), higher stages for IIIB (HR = 7.155, 95% CI 0.960–53.334), and IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354), history of not undergoing surgical intervention (HR = 3.999, 95% CI 1.684–9.495), and adjuvant chemotherapy (HR = 2.768, 95% CI 1.211–6.327) have been associated significantly to lower overall survival. Multivariate analysis showed IIIC breast cancer stage as an independent factor and had a significantly increased probability of mortality (HR = 14.677, 95% CI 1.268–169.948).Conclusions: The stage at diagnosis was the only significant predictor for the survival outcome, indicating that early diagnosis may need more attention.
The Identification and Analysis of Adverse Events in Elderly Female Breast Cancer Patients Using Anthracycline-Based Regimens at Dharmais Cancer Hospital Ester Marsaulina Marsaulina; Retnosari Andrajati; Yuri Pertamasari; Alvinda Heriza Nasution
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.898

Abstract

Background: Anthracycline is the first-choice chemotherapy for the treatment of breast cancer, particularly in elderly patients. However, several studies reported adverse events in the treatment of using anthracyclines. This study aims to identify adverse events. It is also to find out more about how independent variables are related to adverse events. Method: An observational retrospective study of elderly patients (≥ 60 years old) was conducted in a tertiary cancer hospital in Jakarta. Data were collected from January 2018 to December 2020. We used an oncology-specific trigger tool to identify adverse events during anthracycline-based regimens. Independent variables were evaluated in univariate analysis: age, weight loss, marital status, total cumulative dose, polypharmacy, types of anthracyclines, and metastatic status. Bivariate and multivariate analyses were conducted to find out the relationship between the independent variables and adverse events.Results: In total, 107 subject records were collected and reviewed. Triggers were identified 122 times in 86 medical records. Blood transfusion, the most common trigger, was found in 35% of subjects. We found the number of triggers and adverse events more commonly identified in the first and second cycles of chemotherapy. The prevalence of adverse events is detected in 80% of subjects. Of these 86 subjects, 74% were detected in doxorubicin and 26% were detected in epirubicin. All the adverse events were categorized as The National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) harm category E.Conclusion: Trigger tools specific for cancer patients can be used to identify adverse events. Blood transfusion was the common trigger to detect adverse events in our study. Adverse events with category E were identified in all the subjects. Neutropenia and anemia were the most common adverse events in all cycles of chemotherapy. Weight loss was the independent variable related to adverse events in elderly breast cancer patients (p <0.003).
A Case Report of Double Primer Cancer: Malignant Phyllodes Tumor and Invasive Ductal Carcinoma Lauraine Wijayaningtyas Sinuraya; Kristanto Yuli Yarso
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.934

Abstract

Introduction: Multiple primaries have been reported in patients with breast cancer in the range of 4.1% to 16.4%. This report followed the standard Surgical Case Report (SCARE) and discussed two histologically distinct breast cancer malignancies. This paper also explored the risk factor, pathogenesis, treatment, and prognosis of multiple primary malignancies in the same organs, especially in the breasts.Case Presentation: The patient was a 45-year-old woman with a lump in the left and right breasts for five years. The patient claimed that the lump was enlarged and painless. The tumor size of the left breast was 3 x 2 x 3 cm, the right breast was 4 x 2 x 4 cm, and the patient had no enlargement of lymph nodes. The patient underwent a biopsy examination of the left breast showing invasive ductal carcinoma NST (No Special Type) 3rd grade with LV1 (+). The biopsy examination of the right breast showed malignant phyllodes tumor. Thus, the patient must undergo chemotherapy and mastectomy as definitive therapy. The patient has already completed the treatment and is currently under evaluation.Conclusion: This report looked for the rare case of double primary malignancies in the breasts. It highlighted double primary cancers starting to increase these days but in a particular way because it happens in the same organ, the breasts. However, medical literature rarely presented a synchronous malignancy case, prompting the publishing of this case. With improved cancer treatment and more prolonged survival, the number of patients with double cancers is increasing.
CD4+ and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Biomarkers: Role in Predicting the Stadium and Prognosis of Cervical Cancer Humairah Medina Liza Lubis; Rafa Nabila Haifa; Rizky Yusfasari; Muhammad Zikri Agung Ramadhan
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.906

Abstract

Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.
Kidney Cancer Profile in National Cancer Center (NCC) - Dharmais Cancer Hospital Diki Arma Duha; Edward Usfie Harahap; Rachmat Budi Santoso; Ikhlas Arief Bramono
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.904

Abstract

Background: Kidney cancer is one of the most prevalent cancers in urology. The higher prevalence of risk factors, as well as better diagnostic modalities, has led to a reported increase worldwide. The study aims to describe the profile and management pattern of kidney cancer patients at a tertiary referral center over seven years.Methods: A descriptive study was conducted to assess the profile and management of kidney patients in the national cancer center (NCC) - Dharmais Hospital Jakarta between January 2013 and December 2020. The variables collected included age, gender, stage (AJCC staging), histopathological result, and management, using the total sampling method.Results: A total of 53 kidney cancer cases were documented in NCC - Dharmais Hospital Jakarta from 2013 to 2020. Overall, males are more prevalent than females, with a sex ratio of 2.3:1. The most frequent age group was 51–65 years. The most common histological subtype was a clear cell in the renal cell carcinoma (RCC) subtype and sarcoma in the non-RCC subtype. Noticeably, end-stage (stage IV) was found in more than half of patients (65.6%), with no patient found in stage I. Radical nephrectomy was preferable to cytoreductive nephrectomy. Conclusions: : An increasing trend of kidney cancer incidence was found between 2013 and 2020 with most patients diagnosed with stage IV.
Embryo Cryopreservation as an Alternative to Treat Infertility in Breast Cancer Survivors in Reproductive Age: Case Reports Dwirani Rosmala Pratiwi; Noer Halimatus Syakdiyah; Ario Djatmiko; Lia Natalia Hinting
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.935

Abstract

Introduction: Chemotherapy has been shown to reduce breast cancer (BC) mortality significantly. However, several types of chemotherapy drugs affect the reproductive system. As BC has become increasingly prevalent, many young women are diagnosed during their reproductive years. As a result, overcoming chemotherapy-related infertility is becoming increasingly important. Hence, in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy is considered a way to preserve future reproductive potential. For this reason, this paper aims to report the cases of safe pregnancy in BC survivors through pre-chemotherapy IVF followed by embryo cryopreservation.Case Presentation: Two women, aged 35 and 29, respectively, were treated for BC by surgery, chemotherapy, and tamoxifen. They performed in-vitro fertilization (IVF) with embryo cryopreservation before chemotherapy. Their pregnancy was completed without complications, and they gave birth to healthy babies. Their last oncological visit also showed no signs of cancer recurrence, showing disease-free intervals of seven and eight years, respectively.Conclusions: Pre-chemotherapy IVF followed by embryo cryopreservation can be an alternative to treat infertility in BC survivors of reproductive age who are receiving chemotherapy.
Characteristics of Breast Cancer in Young Female Patients in Dr. Mohammad Hoesin General Hospital Palembang Atik Diah Mutiara Ningsih; Nur Qodir; Ahmat Umar; Mulawan Umar; Puji Rizki Suryani; Citra Dewi
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.907

Abstract

Background: Breast cancer has had the highest mortality and morbidity globally in recent years. Breast cancer in young women presents with biological characteristics of more aggressive cancer, generally detected at advanced stage and a poorer prognosis. This study aimed to determine the characteristics of the incidence of breast cancer in young female patients at Dr. Mohammad Hoesin General Hospital Palembang in 2019–2020.Methods: This study is descriptive observational study conducted in October–November 2021. After having ethical approval from the Institutional Review Committee, research data were obtained from the medical records of young female patients diagnosed with breast cancer from January 1, 2019 to December 31, 2020. Samples were collected by using total sampling with the patient’s young age limit of fewer than 40 years.Results: The incidence of breast cancer was 20.9% (169 patients). The number of samples in this study was 120. Sociodemographic characteristics include the age range of 35–39 years around 63.3% (76 people), the highest education level of senior high school around 35% (42 people), not working around 73.3% (88 people), and living in the Palembang City area around 47.5% (57 people). Clinicopathological characteristics include the stage at the first diagnosis of stage IIIB about 46.7% (56 people), luminal B clinical subtype about 60% (72 people), and most histopathological type of invasive carcinoma of no special type about 88.3% (106 people).Conclusions: The incidence of breast cancer in young women is less than in older women but has worse cancer characteristics
Free Tissue Transfer in Patients with Hematologic Malignancies: A Case Series Azmi Ritana; Dewi Aisiyah Mukarramah; Muhammad Irsyad Kiat; Kasih Rahardjo Djarot; Irena Sakura Rini; Resti Mulyasari; Oskar Ady Widarta
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.913

Abstract

Introduction: Free tissue transfer performed in patients with hematologic malignancies has several considerable challenges. Studies that report the challenges and outcomes related to these patients have been rather limited. This study presents the outcome of free tissue transfer as the reconstructive option for patients with hematologic malignancies. This study reports our experience regarding the perioperative evaluation, management, and outcomes of five patients with hematological malignancies that underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia. Case Presentation: Five patients with hematologic malignancies, aged 26 to 60 years, who underwent free tissue transfer at Dharmais Cancer Hospital-National Cancer Center, Jakarta, Indonesia from January 2017 to February 2020 were included. The outcomes such as flap survival, complications, and mortality were reviewed. There were three patients with NonHodgkin lymphoma (NHL), one patient with peripheral T-cell lymphoma, and one patient with acute myeloid leukemia (AML). All patients received free tissue transfer with flap modalities such as radial free forearm flap and anterolateral thigh. One patient had a postoperative complication of vein compromise and was treated with negative pressure wound therapy (NPWT), which resulted in partial flap necrosis. Dehiscence was also found in one patient, and the patient underwent reoperation. Then, a myocutaneous trapezius flap was applied. There was no total flap loss, no donor site morbidity, and no mortality. Conclusions: This study has shown that free tissue transfer was a reliable reconstructive option for patients with hematologic malignancies. Flap survival and minimal complications can be achieved by optimizing the patient’s condition preoperatively, performing the meticulous nontraumatic surgical technique, closely monitoring potential post-operative complications, and implementing a multidisciplinary approach with the hematooncologists.
Resection of Anaplastic Meningioma via Combined Craniofacial Approach Yosafat Kurniawan Sugiarto; Arwinder Singh; Muhammad Firdaus; Oskar Ady Widarta; Farilaila Rayhani
Indonesian Journal of Cancer Vol 16, No 4 (2022): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v16i4.910

Abstract

Introduction: Meningiomas are common and mostly benign intracranial tumors but may show a histological progression to malignancy. The mechanism of malignant transformation remains unclear. Malignant meningiomas usually bear a high recurrence rate and unfavorable prognosis; hence, multiple surgical resections are required for the treatmentCase Presentation: A 41-year-old woman with a prior history of craniotomy at another center six years ago with Meningioma Grade 1 presented to our institution with new neurological symptoms. The magnetic resonance image demonstrated a large frontal base mass that extended to the nasal cavity with diffuse contrast enhancement and extensive surrounding edema. A craniofacial approach combined with a bifrontal approach was performed in multistage tumor resection. The tumor and the infiltrated dura were radically removed. The histopathology demonstrated an Anaplastic Meningioma. The patient also underwent radiation therapy.Conclusion:  Treatment of recurrent meningioma with anaplastic histology remains challenging because recurrence rates remain high with a poor prognosis.

Page 1 of 2 | Total Record : 12

 1   2 

Filter by Year

2022 2022


Reset
Filter By Issues
All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue